Novartis Signs Development Deal With Cell Therapeutics For Xyotax
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis and CTI will develop and commercialize poliglumex paclitaxel, currently in Phase III for non-small cell lung cancer in women.
You may also be interested in...
Xyotax Retains Fast Track Status For Certain Female Lung Cancer Patients
Trials of Xyotax in women with lung cancer who have normal estrogen levels are landmark studies using estrogen as a biomarker, CTI says.
Xyotax Retains Fast Track Status For Certain Female Lung Cancer Patients
Trials of Xyotax in women with lung cancer who have normal estrogen levels are landmark studies using estrogen as a biomarker, CTI says.
Cell Therapeutics CEO James Bianco: An Interview With “The Pink Sheet” DAILY
Seattle biotech is looking to “build a more integrated portfolio” with offer to purchase Miami-based DOR BioPharma, Bianco says.